



Food and Drug Administration
Rockville, MD 20857

November 22, 2004

David G. Adams
IVAX Pharmaceuticals, Inc.
575 F Street, NW
Washington, DC 20004-1601

Dear Mr. Adams:

Your petition, on behalf IVAX Pharmaceuticals, Inc. requesting the Food and Drug Administration to confirm that IVAX is 180-Day Exclusivity for Ipratropium Bromide and Albuterol Sulfate Inhalation solution, was received by this office on 11/22/2004. It was assigned docket number 2004P-0520/CP1 and it was filed on 11/22/2004. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

/s/

Jennie C. Butler, Director
Division of Dockets Management
Office of Management Programs
Office of Management